Premium
Mechanisms of Hormonal Prevention of Breast Cancer
Author(s) -
MEDINA DANIEL,
SIVARAMAN LAKSHMI,
HILSENBECK SUSAN G.,
CONNEELY ORLA,
GINGER MELANIE,
ROSEN JEFFREY,
O'MALLEY BERT W.
Publication year - 2001
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2001.tb02725.x
Subject(s) - estrogen , hormone , biology , endocrinology , medicine , breast cancer , estrogen receptor , mammary gland , cancer , cancer research
Reproductive history is a consistent risk factor for human breast cancer. Epidemiological studies have repeatedly demonstrated that early age of first pregnancy is a strong protective factor against breast cancer and provides a physiologically operative model to achieve a practical mode of prevention. In rodents, the effects of full‐term pregnancy can be mimicked by a three‐week exposure to low doses of estrogen and progesterone. Neither hormone alone is sufficient to induce protection. The cellular and molecular mechanisms that underlie hormone‐induced refractoriness are largely unresolved. Our recent studies have demonstrated that an early cellular response that is altered in hormone‐treated mammary cells is the initial proliferative burst induced by the chemical carcinogen methylnitrosourea. The decrease in proliferation is also accompanied by a decrease in the ability of estrogen receptor‐positive cells to proliferate. RNA expression of several mammary cell‐cycle‐related genes is not altered in hormone‐treated mice; however, immunohistochemical assays demonstrate that the protein level and nuclear compartmentalization of the p53 tumor suppressor gene are markedly upregulated as a consequence of hormone treatment. These results support the hypothesis that hormone stimulation, at a critical period in mammary development, results in cells with persistent changes in the intracellular regulatory loops governing proliferation and response to DNA damage. A corollary to this hypothesis is that the genes affected by estrogen and progesterone are independent of alveolar differentiation‐specific genes. Suppressive subtractive hybridization‐PCR methods have identified several genes that are differentially expressed as a consequence of prior estrogen and progesterone treatment. Future experiments are aimed at determining the mechanisms of hormone‐induced upregulation of p53 protein expression as part of the overall goal of identifying and functionally characterizing the genes responsible for the refractory phenotype.